Indeed, in this robust model, methotrexate, anti-TNF antibodies or Abatacept (CTLA-4Ig), that are currently used to treat RA patients, have been shown to ameliorate clinical CIA scores [16–18], rendering it particularly relevant to analyze new immunomodulatory therapeutic regimen. This evidence concerns the gene TNF and rheumatoid arthritis.